Adjuvant trial in melanoma patients comparing rIFN-α to rIFN-γ to Iscador to a control group after curative resection of high risk primary (≥3 MM) or regional lymphnode metastasis (EORTC 18871)
U.R. Kleeberg, Stefan Suciu(St James's University Hospital), Eva-Bettina Bröcker, J.R. Marsden(Birmingham General Hospital), D. Ruiter, F. Lejeune, Christine Egger(Novartis (Switzerland)), Cécile Chartier(Io Therapeutics (United States))
Cited by 61
Related Papers
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2015|1.3k
Inefficacy of Immediate Node Dissection in Stage 1 Melanoma of the Limbs
|New England Journal of Medicine|1977|667
Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli
|Journal of Virology|1996|651